Last updated: 2026-09-09 11:37:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Contineum Therapeutics, Inc. (CTNM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15.95, with a market capitalization of $628.27M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.60 to $17.79. This page covers its latest market performance, valuation, price trends and company information.
$628.27M | |
$16.59 | |
$22.00 | |
$3.35 | |
$16.70 | |
292.14K | |
437.30K | |
-- | |
$17.79 | |
$8.60 | |
-- | |
-- |
Contineum Therapeutics, Inc. (CTNM) is trading at $18.00 in pre-market trading as of 2026-09-08 23:31:00, up 7.78% ($1.30) from the previous close of $16.70
Pre-market trading shows how investors are pricing CTNM before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Contineum Therapeutics, Inc. (CTNM) moved from $17.05 to $15.95, representing a decline of 6.44% ($1.10).
The stock traded between $15.81 and $17.79 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 333.13 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.0%
CTNM is currently trading at $15.95, placing it 80.0% of the way from its 52-week low of $8.60 to its 52-week high of $17.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 51 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Contineum Therapeutics, Inc. (CTNM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.